https://elasmogen.com/ 2026-01-13T12:39:03+00:00 1.00 https://elasmogen.com/news/ 2026-01-13T12:39:03+00:00 0.80 https://elasmogen.com/publications/ 2026-01-13T12:39:03+00:00 0.80 https://elasmogen.com/privacy/ 2026-01-13T12:39:03+00:00 0.80 https://elasmogen.com/2026/01/06/elasmogen-researcher-dr-obinna-ubah-receives-a-further-715k-via-ukris-future-leaders-fellowship-flf-scheme/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2025/09/10/elasmogen-presenting-at-elrig-2025-glasgow/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2025/05/14/elasmogen-presenting-latest-sdc-data-at-antibody-engineering-therapeutics-in-basel-june-10-12th-2025/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2025/05/05/elasmogen-presenting-latest-data-at-pegs-summit-12-16th-may-2025/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2025/03/05/elasmogen-to-present-new-data-at-the-nextgen-biomed-conference-12-14th-march-2025/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2025/03/05/elasmogen-presenting-at-world-adc-conference-in-london-3rd-to-5th-march-2025/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2024/12/04/hands-on-experience-at-elasmogen-for-harlaw-advanced-highers-students/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2024/06/04/first-in-class-bispecific-next-generation-adc-targeting-egfr-ror1-to-progress-into-pre-clinical-development/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2024/04/07/2024-impact-report-the-scottish-national-investment-bank-helps-elasmogen-to-develop-next-generation-therapeutic-drugs/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2023/11/17/harlaw-academy-students-visited-elasmogen/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2023/06/20/elasmogen-has-been-listed-for-for-the-deal-dealmakers-awards/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2023/05/30/elasmogen-team-took-a-part-in-the-regional-event-hosted-by-the-bia-in-collaboration-with-one/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/news/page/2/?et_blog 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/news-archive/ 2026-01-13T12:39:03+00:00 0.64 https://elasmogen.com/2026/01/06/functionalization-of-polymeric-nanoparticles-with-targeting-vnar-ligands-using-vinyl-sulfone-conjugation/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-ltd-are-shortlisted-in-the-obn-best-start-up-biotech-company-awards-2016/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2025/12/17/shark-novel-antigen-receptors-the-next-generation-of-biologic-therapeutics/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2023/04/28/dr-jane-dancer-named-as-the-new-chair-of-elasmogen-ltd/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/news/?et_blog 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/intract-pharma-and-elasmogen-ltd-announce-collaboration-to-discover-and-develop-novel-orally-delivered-protein-therapeutics/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-wins-two-grants-worth-374000/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-announces-grants-of-2-new-vnar-and-solomer-patent-families/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-announces-a-panel-of-novel-potent-anti-covid-19-therapeutic-candidates-identified-through-collaboration-with-u-s-research-partners/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/researcher-in-elasmogen-ltd-receives-prestigious-fellowship-worth-2-m-to-help-establish-him-as-a-future-leader-of-uk-bioscience/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-and-intract-enter-license-agreement-for-soteria-and-phloral-technologies/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-licenses-nduretm-half-life-extension-technology-to-immunoforge/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-ceo-caroline-barelle-interviewed-by-life-sciences-scotland-for-leadership-insight/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/almac-discovery-and-elasmogen-to-share-anti-ror-1-vnar-data-at-american-association-of-cancer-annual-meeting/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/shark-antibody-like-proteins-neutralize-covid-19-virus-help-prepare-for-future-coronaviruses/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-ceo-shortlisted-for-bbsrc-innovator-of-the-year-2019-award/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/elasmogen-ceo-caroline-barelle-named-one-of-top-20-women-in-leading-biotech-roles-in-europe/ 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/news-archive/page/2/?et_blog 2026-01-13T12:39:03+00:00 0.51 https://elasmogen.com/2026/01/06/evaluation-of-variable-new-antigen-receptors-vnars-as-a-novel-cathepsin-s-ctss-targeting-strategy/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ltd-wins-the-perfect-pitch-at-biotrinity-2016/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2025/12/17/characterization-of-the-immunoglobulin-repertoire-of-the-spiny-dogfish-squalus-acanthias/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ltd-to-deploy-their-solomer-technology-platform-to-develop-tools-to-combat-covid-19/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ceo-caroline-barelle-featured-in-news-outlets-as-a-leader-in-biotech-space/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/caroline-barelle-featured-in-insights-success/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/dr-caroline-barelle-named-rising-stars-extraordinary-talent-2017-at-last-nights-scotlands-life-sciences-dinner-annual-awards/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-nominated-for-innovative-collaboration-award-with-almac-discovery/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/almac-discovery-elasmogen-and-innovate-uk-collaborate-to-develop-vnar-based-oncology-platform/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-featured-in-biotechnology-and-biological-sciences-research-council-spinout-report/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ceo-interviewed-by-scottish-business-news-network/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/summit-awards-celebrating-scottish-entrepreneurship/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ceo-dr-caroline-barelle-wins-academic-entrepreneur-of-the-year-award-at-entrepreneurial-scotlands-summit-awards-2018/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-winner-of-biofit-2018-start-up-slams/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/elasmogen-ltd-shark-proteins-for-drug-discovery/ 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/news-archive/page/3/?et_blog 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/news-archive/?et_blog 2026-01-13T12:39:03+00:00 0.41 https://elasmogen.com/2026/01/06/mechanisms-of-sars-cov-2-neutralization-by-shark-variable-new-antigen-receptors-elucidated-through-x-ray-crystallography-2/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2026/01/06/bgf-scottish-national-investment-bank-and-scottish-enterprise-join-forces-to-invest-8m-in-aberdeen-biologics-company-elasmogen/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2025/12/17/generation-and-isolation-of-target-specific-single-domain-antibodies-from-shark-immune-repertoires/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2026/01/06/dr-caroline-barelle-ceo-has-been-selected-as-a-finalist-for-the-rising-stars/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2026/01/06/elasmogen-secures-2-m-funding/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2026/01/06/elasmogen-featured-in-converge-podcast/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/2026/01/06/elasmogen-receives-1-2-m-in-grant-and-equity-investment/ 2026-01-13T12:39:03+00:00 0.33 https://elasmogen.com/wp-content/uploads/2016/03/Elasmogen-Ltd-%E2%80%93-shark-proteins-for-drug-discovery.pdf 2025-11-04T11:43:18+00:00 0.33 https://elasmogen.com/2026/01/06/non-alcoholic-steatohepatitis-nash-a-review-of-a-crowded-clinical-landscape-driven-by-a-complex-disease/ 2026-01-13T12:39:03+00:00 0.26 https://elasmogen.com/2025/12/17/improving-the-pharmacokinetic-properties-of-biologics-by-fusion-to-an-anti-hsa-shark-vnar-domain/ 2026-01-13T12:39:03+00:00 0.26 https://elasmogen.com/2026/01/06/elasmogen-ceo-named-one-of-top-14-female-entrepreneurs-in-european-biotech-by-labiotech-eu/ 2026-01-13T12:39:03+00:00 0.26 https://elasmogen.com/2026/01/06/elasmogen-technology-featured-in-the-times-news/ 2026-01-13T12:39:03+00:00 0.26 https://elasmogen.com/2026/01/06/feldan-therapeutics-and-elasmogen-announce-research-agreement-with-amgen-to-develop-intracellular-biologics/ 2026-01-13T12:39:03+00:00 0.26 https://elasmogen.com/2026/01/06/anti-dll4-vnar-targeted-nanoparticles-for-targeting-of-both-tumour-and-tumour-associated-vasculature/ 2026-01-13T12:39:03+00:00 0.21 https://elasmogen.com/2026/01/06/shark-variable-new-antigen-receptor-biologics-a-novel-technology-platform-for-therapeutic-drug-development/ 2026-01-13T12:39:03+00:00 0.21 https://elasmogen.com/2026/01/06/isolation-of-highly-selective-ignar-variable-single-domains-against-a-human-therapeutic-fc-scaffold-and-their-application-as-tailor-made-bioprocessing-reagents/ 2026-01-13T12:39:03+00:00 0.17 https://elasmogen.com/2026/01/06/vnars-an-ancient-and-unique-repertoire-of-molecules-that-deliver-small-soluble-stable-and-high-affinity-binders-of-proteins/ 2026-01-13T12:39:03+00:00 0.17 https://elasmogen.com/2026/01/06/in-vitro-elisa-and-cell-based-assays-confirm-the-low-immunogenicity-of-vnar-therapeutic-constructs-in-a-mouse-model-of-human-ra-an-encouraging-milestone-to-further-clinical-drug-development/ 2026-01-13T12:39:03+00:00 0.13 https://elasmogen.com/2026/01/06/structural-insights-and-biomedical-potential-of-ignar-scaffolds-from-sharks/ 2026-01-13T12:39:03+00:00 0.13 https://elasmogen.com/2026/01/06/uveitis-therapy-with-shark-variable-novel-antigen-receptor-domains-targeting-tumor-necrosis-factor-alpha-or-inducible-t-cell-costimulatory-ligand/ 2026-01-13T12:39:03+00:00 0.11 https://elasmogen.com/2026/01/06/therapeutic-potential-of-shark-anti-icosl-vnar-domains-is-exemplified-in-a-murine-model-of-autoimmune-non-infectious-uveitis/ 2026-01-13T12:39:03+00:00 0.11 https://elasmogen.com/2026/01/06/oriented-attachment-of-vnar-proteins-via-site-selective-modification-on-plga-peg-nanoparticles-enhances-nanoconjugate-performance/ 2026-01-13T12:39:03+00:00 0.09 https://elasmogen.com/2026/01/06/phage-display-derived-ignar-v-region-binding-domains-for-therapeutic-development/ 2026-01-13T12:39:03+00:00 0.09 https://elasmogen.com/2026/01/06/an-anti-htnf-%ce%b1-variable-new-antigen-receptor-format-demonstrates-superior-in-vivo-preclinical-efficacy-to-humira-in-a-transgenic-mouse-autoimmune-polyarthritis-disease-model/ 2026-01-13T12:39:03+00:00 0.07 https://elasmogen.com/2026/01/06/novel-anti-htnf-%ce%b1-variable-new-antigen-receptor-formats-with-enhanced-neutralizing-potency-and-multifunctionality-generated-for-therapeutic-development/ 2026-01-13T12:39:03+00:00 0.07 https://elasmogen.com/2026/01/06/next-generation-flexible-formats-of-vnar-domains-expand-the-drug-platforms-utility-and-developability/ 2026-01-13T12:39:03+00:00 0.05 https://elasmogen.com/2026/01/06/in-vitro-maturation-of-a-humanized-shark-vnar-domain-to-improve-its-biophysical-properties-to-facilitate-clinical-development/ 2026-01-13T12:39:03+00:00 0.05 https://elasmogen.com/2026/01/06/anti-icosl-new-antigen-receptor-domains-inhibit-t-cell-proliferation-and-reduce-the-development-of-inflammation-in-the-collagen-induced-mouse-model-of-rheumatoid-arthritis/ 2026-01-13T12:39:03+00:00 0.04